iBio (NASDAQ:IBIO) Stock Rating Upgraded by Wall Street Zen

iBio (NASDAQ:IBIO) was upgraded by analysts at Wall Street Zen from a “strong sell” rating to a “hold” rating in a research note issued on Sunday.

Several other research analysts have also recently issued reports on IBIO. Weiss Ratings reissued a “sell (d-)” rating on shares of iBio in a research report on Tuesday. Leerink Partnrs raised shares of iBio to a “strong-buy” rating in a report on Friday, October 17th. One research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, iBio has a consensus rating of “Moderate Buy”.

iBio Price Performance

Shares of IBIO opened at $1.16 on Friday. The firm has a market cap of $23.50 million, a price-to-earnings ratio of -0.67 and a beta of 0.93. iBio has a twelve month low of $0.56 and a twelve month high of $6.89.

iBio (NASDAQ:IBIO) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.04). The business had revenue of $0.10 million during the quarter.

About iBio

iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis.